ライフサイエンスコーパス: indoleamine 2,3-dioxygenase

1 duces depressive-like behavior by activating indoleamine 2,3 dioxygenase.

2 the presence of H(2)O(2)/ONOO(-) deactivated indoleamine 2,3-dioxygenase.

3 of 2',5'-oligoadenylate synthetase, Mx1, and indoleamine 2,3-dioxygenase.

4 cells through the induction and activity of indoleamine 2,3-dioxygenase.

5 t in vitro (though not in vivo) inhibitor of indoleamine 2,3-dioxygenase.

6 a induces expression of p47 GTPases, but not indoleamine 2,3-dioxygenase.

7 hyl-tryptophan which is also an inhibitor of indoleamine 2,3-dioxygenase.

8 eam target, the tryptophan-catalyzing enzyme indoleamine 2,3-dioxygenase.

9 eries of substituted tryptophan analogues by indoleamine 2,3-dioxygenase.

10 were evaluated for their ability to inhibit indoleamine 2,3-dioxygenase.

11 xpression of the tryptophan-degrading enzyme indoleamine-2,3-dioxygenase.

12 ited T-cell reactivity through regulation of indoleamine-2,3-dioxygenase.

13 ulatory molecules including IL-10, CD25, and indoleamine-2,3-dioxygenase.

14 tryptophan via the IFN-gamma-induced enzyme indoleamine 2, 3-dioxygenase.

15 was not mediated via induction of the enzyme indoleamine 2, 3-dioxygenase.

16 endent on the tryptophan catabolizing enzyme indoleamine 2,3 dioxygenase 1 (IDO1) in splenic macropha

17 Human indoleamine 2,3-dioxygenase 1 (hIDO1) is an attractive c

18 Since the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) as an attractive ta

19 ses of two antiretroviral ISGs indicate that indoleamine 2,3-dioxygenase 1 (IDO1) can inhibit retrovi

20 as driven by IFN-gamma-mediated induction of indoleamine 2,3-dioxygenase 1 (IDO1) enzyme activity wit

21 Indoleamine 2,3-dioxygenase 1 (IDO1) is a key regulatory

22 Indoleamine 2,3-dioxygenase 1 (IDO1) is a single chain o

23 Indoleamine 2,3-dioxygenase 1 (IDO1) is an important the

24 Here, we report that brain indoleamine 2,3-dioxygenase 1 (IDO1), a rate-limiting en

25 tion, a host tryptophan-catabolizing enzyme, indoleamine 2,3-dioxygenase 1 (IDO1), is induced specifi

26 Indoleamine 2,3-dioxygenase 1 (IDO1), promoting immune e

27 ystemic inflammation only in the presence of indoleamine 2,3-dioxygenase 1 (IDO1).

28 asmid against the immunosuppressive molecule indoleamine 2,3-dioxygenase 1 (shIDO).

29 hermore, treatment of NKp44(+) NK cells with indoleamine 2,3-dioxygenase 1 catabolites in vitro ablat

30 inflammatory mediators in the gut, including indoleamine 2,3-dioxygenase 1.

31 Indoleamine 2,3 dioxygenase-1 (IDO-1) is an enzyme in th

32 Indoleamine 2,3 dioxygenase-1 (IDO1) catabolizes tryptop

33 y are associated with elevated expression of indoleamine 2,3 dioxygenase-1 (IDO1).

34 munodeficiency virus (HIV) infection-induced indoleamine 2,3-dioxygenase-1 (IDO) expression in activa

35 Small-molecule inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) are emerging at the

36 Indoleamine 2,3-dioxygenase-1 (IDO1; IDO) mediates oxida

37 ols, whereas level of messenger RNA encoding indoleamine 2,3-dioxygenase-1 was significantly increase

38 , the SE inhibited the enzymatic activity of indoleamine 2,3 dioxygenase, a key enzyme in immune tole

39 n-gamma-induced degradation of tryptophan by indoleamine 2,3-dioxygenase, activates the previously or

40 Increased indoleamine 2,3-dioxygenase activity and consequent indu

41 cts of gamma interferon (IFN-gamma)-mediated indoleamine 2,3-dioxygenase activity on C. pneumoniae pe

42 The indoleamine 2,3-dioxygenase activity was assessed by mas

43 cells, possibly via stimulation of host cell indoleamine-2,3-dioxygenase activity, in a dose-dependen

44 e, is similar to that of the large domain of indoleamine 2,3-dioxygenase, an enzyme that catalyzes th

45 lls express high levels of CD163, CD206, and indoleamine 2,3-dioxygenase and secrete immunosuppressiv

46 grafts and increased expression of mRNAs for indoleamine 2,3-dioxygenase and the subunits encoding in

47 is an O2-dependent process and catalyzed by indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygena

48 g induction was mediated by DC expression of indoleamine 2,3-dioxygenase, and was confirmed in IDO-KO

49 of various tumor-promoting genes, including indoleamine 2,3-dioxygenase; and attenuation of these ch

50 ot reverse tolerance, but treatment with the indoleamine-2,3-dioxygenase antagonist 1-methyltryptopha

51 expression of tolerogenic mediators, such as indoleamine-2,3-dioxygenase, arginase, and TGF-beta, and

52 With TDO and Indoleamine 2,3-dioxygenase as evolutionarily conserved

53 Inhibition of placental indoleamine 2,3-dioxygenase by 1-methyl-tryptophan preve

54 sistent with a common reaction mechanism for indoleamine 2,3-dioxygenase-catalyzed oxidation of trypt

55 Indoleamine 2,3-dioxygenase catalyzes the O(2)-dependent

56 r- beta 1+ cells, interleukin-10+ cells, and indoleamine 2,3-dioxygenase+CD3+ cells.

57 Potential roles for indoleamine 2,3-dioxygenase, costimulatory molecules, an

58 physiological importance of human placental indoleamine 2,3-dioxygenase (EC 1.13.11.42), the first a

59 lation of circulating prostaglandin E(2) and indoleamine 2, 3,-dioxygenase enzymatic activity, as wel

60 IL-27-induced indoleamine 2,3-dioxygenase enzymatic activity leads to

61 but not sequence homology to the two-domain indoleamine 2,3-dioxygenase enzyme (IDO).

62 on an omega-3 fatty acid derivative inducing indoleamine 2,3-dioxygenase expression in DC.

63 In human epithelial cells, IFN-gamma induces indoleamine 2,3-dioxygenase expression that inhibits chl

64 feron-gamma, which increases villous explant indoleamine 2,3-dioxygenase expression, has no effect on

65 ve increased accumulation of CD11c cells and indoleamine 2,3-dioxygenase expression.

66 that inhibition of enzyme activity in human indoleamine 2,3-dioxygenase (hIDO) and a number of site-

67 Human indoleamine 2,3-dioxygenase (hIDO) is an intracellular h

68 Human indoleamine 2,3-dioxygenase (hIDO) is an intracellular h

69 han 2,3 dioxygenase (hTDO), and the other is indoleamine 2,3-dioxygenase (hIDO), both of which cataly

70 nt in heme-based dioxygenases, such as human indoleamine 2,3-dioxygenase (hIDO), was not recognized u

71 in humans: tryptophan dioxygenase (hTDO) and indoleamine 2,3-dioxygenase (hIDO).

72 teins, tryptophan 2,3-dioxygenase (hTDO) and indoleamine 2,3-dioxygenase (hIDO).

73 proved SB transposon encoding the human gene indoleamine-2,3-dioxygenase (hIDO), an enzyme that posse

74 HS suppressed mRNA and protein expression of indoleamine 2, 3-dioxygenase (IDO) and its activity upon

75 Production of indoleamine 2, 3-dioxygenase (IDO) by macrophages has re

76 recently shown that expression of the enzyme indoleamine 2, 3-dioxygenase (IDO) during murine pregnan

77 Indoleamine 2, 3-dioxygenase (IDO) is an immunoregulator

78 y modulating the expression of PD-L1; Tim-3; indoleamine 2, 3-dioxygenase (IDO); and interleukin 10.

79 The enzyme indoleamine 2, 3-dioxygenase (IDO-1) initiates and regul

80 , depletion of Gr1(+) cells or inhibition of indoleamine 2,3 dioxygenase (IDO) activity abrogates gra

81 Indoleamine 2,3 dioxygenase (IDO) activity during pregna

82 amino acid TRP, cells expressing the enzyme indoleamine 2,3 dioxygenase (IDO) can mediate potent loc

83 Indoleamine 2,3 dioxygenase (IDO) catabolizes the amino

84 Indoleamine 2,3 dioxygenase (IDO) has emerged as an impo

85 d expression of the immune regulatory enzyme indoleamine 2,3 dioxygenase (IDO) in local lymph nodes.

86 Indoleamine 2,3 dioxygenase (IDO) is a catabolic enzyme

87 xpression of the tryptophan-degrading enzyme indoleamine 2,3 dioxygenase (IDO) is selectively induced

88 ha(-/-) mice was likely because of a lack of indoleamine 2,3 dioxygenase (IDO), a critical regulator

89 local draining lymph nodes (dLNs) to express indoleamine 2,3 dioxygenase (IDO), which confers T cell

90 aneously, pDCs up-regulate the expression of indoleamine 2,3 dioxygenase (IDO), which is essential fo

91 The roles of anergy and the indoleamine 2,3 dioxygenase (IDO)-tryptophan pathway in

92 tivating immunoregulatory mechanisms such as indoleamine 2,3 dioxygenase (IDO).

93 ressive factors IL-4, IL-10, CD274/PD-L1 and indoleamine 2,3 dioxygenase (IDO).

94 Pharmacological inhibition of indoleamine 2,3-dioxygenase (IDO) activity during murine

95 ther gamma interferon (IFN-gamma) can induce indoleamine 2,3-dioxygenase (IDO) activity in aortic smo

96 higher levels of gamma interferon-inducible indoleamine 2,3-dioxygenase (IDO) activity than endothel

97 ike receptor (TLR) 4 signaling, can regulate indoleamine 2,3-dioxygenase (IDO) activity, favoring TH2

98 (IgM), cytokine/granzyme concentrations, and indoleamine 2,3-dioxygenase (IDO) activity.

99 cells could be attributed to their increased indoleamine 2,3-dioxygenase (IDO) activity.

100 describe a subset of human APCs that express indoleamine 2,3-dioxygenase (IDO) and inhibit T cell pro

101 h a focus on the tryptophan catabolic enzyme indoleamine 2,3-dioxygenase (IDO) and its recently disco

102 inhibitory effect was primarily mediated by indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2 (

103 omotes immune suppression through the enzyme indoleamine 2,3-dioxygenase (IDO) and subsequent product

104 tivated inflammatory macrophages can express indoleamine 2,3-dioxygenase (IDO) and thus actively depl

105 Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dio

106 ortage of tryptophan caused by expression of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dio

107 eprogramming was suppressed by tumor-induced indoleamine 2,3-dioxygenase (IDO) and vaccination failed

108 Small-molecule inhibitors of indoleamine 2,3-dioxygenase (IDO) are currently being tr

109 Indoleamine 2,3-dioxygenase (IDO) catalyzes the breakdow

110 Indoleamine 2,3-dioxygenase (IDO) catalyzes the initial,

111 Tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO) constitute an importan

112 aneous efficacy of serum and urine biomarker indoleamine 2,3-dioxygenase (IDO) enzyme activity and pe

113 CR analysis revealed a 5-fold enhancement of indoleamine 2,3-dioxygenase (IDO) expression in the tumo

114 Additionally, indoleamine 2,3-dioxygenase (IDO) expression was only mo

115 Indoleamine 2,3-dioxygenase (IDO) has immunoregulatory r

116 vation of the tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) in cancer cells facili

117 ously shown that an immunomodulatory enzyme, indoleamine 2,3-dioxygenase (IDO) in dermal fibroblasts

118 rucial role for the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) in GVHD regulation.

119 tent to express the T-cell regulatory enzyme indoleamine 2,3-dioxygenase (IDO) in mice treated with T

120 upregulated both the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) in plasmacytoid DCs an

121 critical role for the immune escape mediator indoleamine 2,3-dioxygenase (IDO) in supporting inflamma

122 Elevation of the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) in tumor cells can fac

123 n 4 (CTLA-4) blockade and treatment with the indoleamine 2,3-dioxygenase (IDO) inhibitor 1-methyl-D-t

124 n a prodrug conjugate of PEG with NLG919, an indoleamine 2,3-dioxygenase (IDO) inhibitor currently us

125 nt and include chemotherapeutics, radiation, indoleamine 2,3-dioxygenase (IDO) inhibitors, inhibitors

126 Indoleamine 2,3-dioxygenase (IDO) is a heme-containing d

127 Indoleamine 2,3-dioxygenase (IDO) is a heme-containing e

128 The heme enzyme indoleamine 2,3-dioxygenase (IDO) is a key regulator of

129 Indoleamine 2,3-dioxygenase (IDO) is a negative regulato

130 The immunosuppressive protein indoleamine 2,3-dioxygenase (IDO) is a rate-limiting enz

131 Indoleamine 2,3-dioxygenase (IDO) is a unique cytosolic

132 Indoleamine 2,3-dioxygenase (IDO) is an immunosuppressiv

133 bolism of the amino acid tryptophan (Trp) by indoleamine 2,3-dioxygenase (IDO) is considered an impor

134 Indoleamine 2,3-dioxygenase (IDO) is emerging as an impo

135 The immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) is expressed by a subs

136 The immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) is expressed by APCs a

137 The tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) is expressed in macrop

138 y, expression of the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) is induced following i

139 Indoleamine 2,3-dioxygenase (IDO) is one molecular mecha

140 Indoleamine 2,3-dioxygenase (IDO) is the enzyme that cat

141 Indoleamine 2,3-dioxygenase (IDO) is the first and rate-

142 Indoleamine 2,3-dioxygenase (IDO) is the first and rate-

143 Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting e

144 Here, we examine the inhibitory role of indoleamine 2,3-dioxygenase (IDO) on the antitumor effic

145 well as interfering in the immunosuppressive indoleamine 2,3-dioxygenase (IDO) pathway.

146 Tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO) play a central role in

147 The heme enzyme indoleamine 2,3-dioxygenase (IDO) plays an important imm

148 ors of the tryptophan (Trp) catabolic enzyme indoleamine 2,3-dioxygenase (IDO) represent a vanguard o

149 Dendritic cell-derived indoleamine 2,3-dioxygenase (IDO) suppresses naive T cel

150 s study, we investigated the relationship of indoleamine 2,3-dioxygenase (IDO) systemic activity on c

151 The heme enzyme indoleamine 2,3-dioxygenase (IDO) was found to catalyze

152 In vivo blockade of indoleamine 2,3-dioxygenase (IDO) was performed, and its

153 In contrast, we found that the induction of indoleamine 2,3-dioxygenase (IDO) was required for the a

154 the tolerogenic tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO) were analyzed using fl

155 ithelial infection by inducing expression of indoleamine 2,3-dioxygenase (IDO), a host enzyme with pr

156 sed antitumor response through inhibition of indoleamine 2,3-dioxygenase (IDO), a key tolerogenic enz

157 The expression of indoleamine 2,3-dioxygenase (IDO), a known immunosuppres

158 duct brassinin to be a moderate inhibitor of indoleamine 2,3-dioxygenase (IDO), a new cancer immunosu

159 Indoleamine 2,3-dioxygenase (IDO), a potent immunosuppre

160 Br-brassinin) are bioavailable inhibitors of indoleamine 2,3-dioxygenase (IDO), a pro-toleragenic enz

161 s to HDAC inhibitors increased expression of indoleamine 2,3-dioxygenase (IDO), a suppressor of DC fu

162 through pathogen-specific local induction of indoleamine 2,3-dioxygenase (IDO), a tryptophan cataboli

163 re treated with a pharmacologic inhibitor of indoleamine 2,3-dioxygenase (IDO), a tryptophan-cataboli

164 ad7-deficient DCs expressed higher levels of indoleamine 2,3-dioxygenase (IDO), an enzyme associated

165 at M. tuberculosis induced the expression of indoleamine 2,3-dioxygenase (IDO), an enzyme involved in

166 blot analysis, which indicated induction of indoleamine 2,3-dioxygenase (IDO), an enzyme that conver

167 One ISG candidate, indoleamine 2,3-dioxygenase (IDO), an IFN-gamma-induced

168 Similar to CTLA-4 and FoxP3, expression of indoleamine 2,3-dioxygenase (IDO), an immunosuppressive

169 Indoleamine 2,3-dioxygenase (IDO), an interferon gamma-i

170 sing T cells (CARTs) through the activity of indoleamine 2,3-dioxygenase (IDO), an intracellular enzy

171 l-molecule immunotherapy agent that inhibits indoleamine 2,3-dioxygenase (IDO), encapsulated in the n

172 yptophan catabolism, initiated by the enzyme indoleamine 2,3-dioxygenase (IDO), is a critical partici

173 Although the tryptophan-degrading enzyme, indoleamine 2,3-dioxygenase (IDO), is a pivotal mediator

174 ted reduced toxicity as reflected by induced indoleamine 2,3-dioxygenase (IDO), suggesting discreet a

175 Indoleamine 2,3-dioxygenase (IDO), the first and rate-li

176 induce an IFNgamma-driven induction of host indoleamine 2,3-dioxygenase (IDO), the first and rate-li

177 We studied the expression of indoleamine 2,3-dioxygenase (IDO), the first enzyme in t

178 n of innate immunity, induces high levels of indoleamine 2,3-dioxygenase (IDO), the rate-limiting enz

179 f expressing the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO), which allows them to

180 Indoleamine 2,3-dioxygenase (IDO), which degrades trypto

181 C production of the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO), which depletes local

182 ations of RV-PV dysfunction with circulating indoleamine 2,3-dioxygenase (IDO)-dependent tryptophan m

183 ptophan oxidation products produced from the indoleamine 2,3-dioxygenase (IDO)-mediated kynurenine pa

184 ession of the tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase (IDO).

185 l expression of the immunosuppressive enzyme indoleamine 2,3-dioxygenase (Ido).

186 s) up-regulate the immune-inhibitory enzyme, indoleamine 2,3-dioxygenase (IDO).

187 s a key pharmacophore in novel inhibitors of indoleamine 2,3-dioxygenase (IDO).

188 family of homologous enzymes, which includes indoleamine 2,3-dioxygenase (IDO).

189 LNs can express the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO).

190 his tolerance is the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO).

191 essed immunosuppressive levels of the enzyme indoleamine 2,3-dioxygenase (IDO).

192 expression of tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase (IDO).

193 in RA patients partly via the production of indoleamine 2,3-dioxygenase (IDO).

194 te-limiting enzyme of tryptophan catabolism, indoleamine 2,3-dioxygenase (IDO).

195 use tryptophan-catabolizing enzymes such as indoleamine 2,3-dioxygenase (IDO-1) to induce an immunos

196 oring of tryptophan (trp) metabolism through indoleamine 2.3-dioxygenase (IDO) has been previously pr

197 uced inducible nitric oxide synthase (iNOS), indoleamine-2,3-dioxygenase (IDO) and heme oxygenase (HO

198 Indoleamine-2,3-dioxygenase (IDO) and tryptophanyl-tRNA-

199 Expression of indoleamine-2,3-dioxygenase (IDO) by vascular endotheliu

200 The enzyme indoleamine-2,3-dioxygenase (IDO) catalyses degradation

201 t levo-1-methyl tryptophan (L-1MT) can block indoleamine-2,3-dioxygenase (IDO) expressed by human den

202 the tumor tissue by the rate-limiting enzyme indoleamine-2,3-dioxygenase (IDO) expressed in tumor cel

203 yptophan pools by gamma interferon-inducible indoleamine-2,3-dioxygenase (IDO) is believed to be the

204 ryptophan and kynurenine, metabolites of the indoleamine-2,3-dioxygenase (IDO) pathway.

205 roids augment MSC expression and activity of indoleamine-2,3-dioxygenase (IDO), a primary mediator of

206 Expression of indoleamine-2,3-dioxygenase (IDO), an immunosuppressive

207 m the induction of type I IFN-alpha/beta and indoleamine-2,3-dioxygenase (IDO)-mediated immunosuppres

208 ting environment via induction of the enzyme indoleamine-2,3-dioxygenase (IDO).

209 ibitor of the tryptophan catabolizing enzyme indoleamine-2,3-dioxygenase (IDO).

210 ential target as the immunoregulatory enzyme indoleamine-2,3-dioxygenase (IDO).

211 ession of the tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO1) in human epithelial c

212 Indoleamine 2,3-dioxygenase (IDO1) is a tryptophan (Trp)

213 Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO1) is an important mecha

214 he anti-inflammatory and anti-bacterial gene indoleamine 2,3-dioxygenase (IDO1) is dependent on STAT1

215 al burdens than control mice, underexpressed indoleamine-2,3-dioxygenase (Ido1) in lung endothelium a

216 in the promoter region of the gene encoding indoleamine-2,3-dioxygenase (IDO1) was found to be assoc

217 on (IFN)-gamma induces the expression of the indoleamine 2, 3-dioxygenase (INDO) gene in human cells,

218 Indoleamine 2,3-dioxygenase (INDO) is the rate-limiting

219 ally sensitive to immunopharmacotherapy with indoleamine 2,3-dioxygenase inhibitors.

220 We measured indoleamine 2,3-dioxygenase, interleukin-6, and transfor

221 n (which is a known competitive inhibitor of indoleamine 2,3-dioxygenase) is a competitive inhibitor

222 ed during tryptophan metabolism initiated by indoleamine 2,3-dioxygenase, is known to induce T cell d

223 Abnormal tryptophan metabolism catalyzed by indoleamine 2,3-dioxygenase may play a prominent role in

224 ance of L-tryptophan transport for placental indoleamine 2,3-dioxygenase-mediated degradation of L-tr

225 nts both BCH and 1-methyl-tryptophan inhibit indoleamine 2,3-dioxygenase-mediated L-tryptophan degrad

226 e trophoblast to be a rate-limiting step for indoleamine 2,3-dioxygenase-mediated L-tryptophan degrad

227 his mechanism is dependent both on placental indoleamine 2,3-dioxygenase-mediated tryptophan degradat

228 cyte division was specifically suppressed by indoleamine 2,3-dioxygenase-mediated tryptophan depletio

229 also inhibited PIV3, including IFITM1, IDO (indoleamine 2,3-dioxygenase), PKR (protein kinase, RNA a

230 rs such as TGF-beta, CTLA-4, PD-1, ICOS, and indoleamine 2,3-dioxygenase play an important role in im

231 Indoleamine 2,3-dioxygenase plays a key role in local tr

232 FN-gamma synthesis by donor T cells inducing indoleamine 2,3-dioxygenase synthesis by donor pDCs limi

233 ane vesicles as part of a study on placental indoleamine 2,3-dioxygenase, the L-tryptophan-catabolisi

234 ending on IFNgamma signaling and mediated by indoleamine 2,3-dioxygenase to a constitutive mechanism

235 ence of interferon-gamma (known to stimulate indoleamine 2,3-dioxygenase) tryptophan but not threonin

236 leged media, which related to A20 preventing indoleamine 2,3-dioxygenase upregulation in SMC.

237 Indoleamine 2,3-dioxygenase was expressed on background

238 explants was markedly reduced when placental indoleamine 2,3-dioxygenase was stimulated with interfer

239 a number of suppressive enzymes, among which indoleamine 2,3-dioxygenase was sufficient to inhibit an

240 ic cell accumulation, expression of IL-2 and indoleamine 2,3-dioxygenase were evident in TLR4 compare

241 ly produced by both cell populations, unlike indoleamine 2, 3-dioxygenase which was only produced fol

242 ophan limitation mediated by the host enzyme indoleamine 2,3-dioxygenase, which converts l-tryptophan

243 and primarily dependent on pDC expression of indoleamine 2,3-dioxygenase, which was induced through t

244 tor-kappaB, as well as the metabolic enzyme, indoleamine-2,3-dioxygenase, which breaks down tryptopha

245 uman (hIDO) and Shewanella oneidensis (sIDO) indoleamine 2,3-dioxygenases, Xanthomonas campestris (Xc